Benitec Biopharma (NASDAQ: BNTC) director gifts 51,813 shares to donor-advised fund

Rhea-AI Filing Summary

Benitec Biopharma Inc. director J. Kevin Buchi reported a charitable stock gift. On June 29, 2026, he transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a Section 501(c)(3) charitable organization as a bona fide gift at no stated price. After this transfer, he directly holds 52,097 common shares. This is a non-market, charitable disposition rather than an open-market sale.

Insights

Equity compensation and governance analyst

Director makes large charitable gift of BNTC shares, not a market sale.

The filing shows director J. Kevin Buchi made a bona fide gift of 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a Section 501(c)(3) charity. The transaction price per share is listed as $0.0000, consistent with a gift rather than a sale.

Following the transfer, he directly holds 52,097 common shares, so he retains a meaningful equity stake. Because this is a charitable gift and not an open-market transaction, it carries limited informational value about his view of the stock and does not change the company’s financials.

Subsequent filings may provide updates if his remaining holdings change through future purchases, sales, or additional gifts, but this specific transaction is best viewed as personal philanthropic activity.

Insider Trade Summary

51,813 shares gifted

Mixed 1 txn

Insider BUCHI J KEVIN

Role null

Type	Security	Shares	Price	Value
Gift	Common Stock	51,813	$0.00	--

Holdings After Transaction: Common Stock — 52,097 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares gifted: 51,813 shares Transaction price per share: $0.0000 per share Shares held after transaction: 52,097 shares +2 more

5 metrics

Shares gifted 51,813 shares Bona fide gift of common stock on June 29, 2026

Transaction price per share $0.0000 per share Gift transfer of Benitec Biopharma common stock

Shares held after transaction 52,097 shares Director’s direct common stock holdings following the gift

Gift transaction count 1 transaction Form 4 summary of bona fide gift dispositions

Total gifted shares (summary) 51,813 shares TransactionSummary giftShares reported in Form 4

Key Terms

bona fide gift, donor-advised fund, Section 501(c)(3) of the Internal Revenue Code

3 terms

bona fide gift financial

"transaction code description is listed as "Bona fide gift""

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

donor-advised fund financial

"transferred 51,813 shares ... to a donor-advised fund sponsored by a charitable organization"

A donor-advised fund is a charitable giving account that lets an individual or family deposit cash, stock, or other assets now, get an immediate tax benefit, and then recommend grants to charities over time. Think of it like a private charitable bucket you control without running a charity yourself; investors care because it’s a tax-efficient way to give appreciated securities, can change when and how donated shares enter the market, and affects personal and corporate tax planning.

Section 501(c)(3) of the Internal Revenue Code regulatory

"a charitable organization under Section 501(c)(3) of the Internal Revenue Code"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 04:21 PM Accepted by SEC EDGAR 06/30/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCHI J KEVIN

(Last) (First) (Middle)

C/O BENITEC BIOPHARMA INC.

3940 TRUST WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		G		51,813	D	$0	52,097(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a charitable organization under Section 501(c)(3) of the Internal Revenue Code.

	/s/ J. Kevin Buchi	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Benitec Biopharma (BNTC) disclose for J. Kevin Buchi?

Benitec Biopharma director J. Kevin Buchi disclosed a bona fide gift of 51,813 shares of common stock. The shares were transferred to a donor-advised fund sponsored by a Section 501(c)(3) charitable organization, with no sale price or cash proceeds reported.

Did J. Kevin Buchi sell Benitec Biopharma (BNTC) shares on the market?

No, he did not sell shares on the market. The Form 4 shows a transaction coded as a bona fide gift (Code G), transferring 51,813 common shares to a donor-advised fund, with a reported transaction price of $0.0000 per share.

How many Benitec Biopharma (BNTC) shares does J. Kevin Buchi hold after the gift?

After gifting 51,813 common shares, J. Kevin Buchi directly holds 52,097 Benitec Biopharma shares. This remaining position is reported in the filing as his total direct ownership following the transaction, indicating he still maintains an equity stake in the company.

Who received the gifted Benitec Biopharma (BNTC) shares from J. Kevin Buchi?

The 51,813 gifted Benitec Biopharma common shares were transferred to a donor-advised fund. That fund is sponsored by a charitable organization described as being under Section 501(c)(3) of the Internal Revenue Code, indicating a qualified charitable recipient.

What does transaction code G mean in the Benitec Biopharma (BNTC) Form 4?

Transaction code G in the Form 4 indicates a bona fide gift. In this case, it shows director J. Kevin Buchi transferred 51,813 Benitec Biopharma common shares to a donor-advised charitable fund rather than executing a purchase or sale on the open market.